The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Eli Lilly 's ( LLY +1.58%) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...